HC Wainwright & Co. Reiterates Buy on Processa Pharma, Maintains $8 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Processa Pharma with a Buy and maintains $8 price target.

Analyst UpgradesMay 13 07:00

Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Oculis Holding (OCS)

TipRanksMay 13 05:31

Processa Pharmaceuticals | 10-Q: Quarterly report

Futu NewsMay 10 15:24 · Announcements

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company focused on developing the next gen

GlobeNewswireMay 6 07:00

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a cli

GlobeNewswireApr 30 07:00

Applied Dna Sciences, OptimizeRx, SCWorx Among Healthcare Movers

Seeking AlphaApr 26 09:00